On this page
TRIP12
thyroid hormone receptor interactor 12
TRIP12 encodes a large E3 ubiquitin ligase that regulates protein degradation and plays an essential role in brain development. The TRIP12 gene provides instructions for making an enzyme that tags damaged or misfolded proteins for destruction, helping cells maintain proper protein balance.
TRIP12 is located on the long (q) arm of chromosome 2, at band 2q36.3. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 2 in the library →Overview
TRIP12, or thyroid hormone receptor interactor 12, encodes a member of the E3 ubiquitin ligase family, enzymes responsible for marking proteins for degradation through the ubiquitin-proteasome system. This quality-control mechanism prevents accumulation of faulty proteins that could interfere with cellular processes. The protein was initially identified through its interaction with thyroid hormone receptors, though its role extends far beyond hormone signalling.
Proper TRIP12 function appears particularly critical during brain development. Changes in this gene follow an autosomal dominant inheritance pattern, meaning one altered copy is typically sufficient to cause clinical features. The gene is recognised within UK neurodevelopmental diagnostic pathways, reflecting its established role in conditions affecting cognition and developmental milestones.
What the gene does
The TRIP12 protein functions as an E3 ubiquitin ligase, catalysing the attachment of ubiquitin molecules to target proteins. This molecular tagging marks proteins for degradation by the proteasome, the cell's protein-recycling machinery. Through this activity, TRIP12 helps regulate the abundance of numerous cellular proteins, ensuring that damaged, misfolded, or no-longer-needed proteins are efficiently removed.
Research suggests TRIP12 participates in several quality-control pathways. The protein monitors the structural integrity of other proteins and coordinates their removal when defects are detected. Evidence indicates TRIP12 may also influence cell-cycle progression and DNA-damage responses by controlling the stability of regulatory proteins in these pathways. During neurodevelopment, proper protein turnover regulated by TRIP12 appears essential for establishing and maintaining neuronal connections, though the precise substrates most relevant to brain function remain an active area of investigation.
Video: Genetics 101
Chromosome location
TRIP12 is located on chromosome 2 at position 2q36.3, near the long arm terminus. This chromosomal region contains numerous genes, and structural rearrangements affecting 2q36 are occasionally observed in individuals with developmental conditions. The TRIP12 gene spans a substantial genomic interval, reflecting the large size of the encoded protein.
Protein structure
The TRIP12 protein comprises 2067 amino acids and contains several functionally important regions. The N-terminal portion includes a long disordered region (a flexible, unstructured portion that allows the protein to interact with multiple partners) spanning amino acids 1-398, which may provide flexibility for protein-protein interactions. The central portion features six consecutive ARM repeats (ARM 1 through ARM 6, spanning amino acids 532-779), structural motifs commonly involved in binding partner proteins.
A WWE domain is present at amino acids 797-911, interspersed with another disordered region. Additional disordered regions occur at positions 938-1080, 1407-1433, and 1568-1587, potentially serving regulatory or binding functions. The K-box region (amino acids 1571-1645) may contribute to substrate recognition. The C-terminal HECT domain (amino acids 1960-2067) provides the catalytic activity for ubiquitin transfer, representing the enzymatic core of the E3 ligase function.
Key variants
Pathogenic variants in TRIP12 disrupt the protein's ability to regulate protein degradation effectively. Changes that impair the HECT domain's catalytic activity or alter substrate recognition through the ARM repeats can compromise cellular protein quality control. Both loss-of-function variants and missense changes affecting critical residues have been reported in individuals with neurodevelopmental presentations.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1012C>T | p.Gln338Ter | Pathogenic | ★★☆☆ | Clark-Baraitser syndrome |
c.1651C>T | p.Arg551Ter | Pathogenic | ★★☆☆ | Clark-Baraitser syndrome |
c.2065C>T | p.Gln689Ter | Pathogenic | ★★☆☆ | Clark-Baraitser syndrome |
c.3490dup | p.Ile1164fs | Pathogenic | ★★☆☆ | Inborn genetic diseases |
c.3808del | p.Ser1270fs | Pathogenic/Likely pathogenic | ★★☆☆ | Clark-Baraitser syndrome |
c.399dup | p.Pro134fs | Pathogenic/Likely pathogenic | ★★☆☆ | Clark-Baraitser syndrome |
c.4903C>T | p.Arg1635Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Clark-Baraitser syndrome |
c.4904G>A | p.Arg1635Gln | Pathogenic/Likely pathogenic | ★★☆☆ | Clark-Baraitser syndrome |
c.586_587del | p.Ser196fs | Pathogenic | ★★☆☆ | Clark-Baraitser syndrome |
g.(230683229_230693908)_(230725248_230744697)del | - | Pathogenic | ★☆☆☆ | Clark-Baraitser syndrome |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Variants in TRIP12 are associated with a spectrum of neurodevelopmental conditions. Clinical features typically include intellectual disability of varying severity and developmental delay affecting motor and language milestones. Some individuals present with additional features such as distinctive facial characteristics, feeding difficulties in infancy, or structural brain differences on imaging such as corpus callosum abnormalities. The range of severity can vary, and not all individuals with pathogenic TRIP12 variants exhibit identical clinical presentations.
No disease links recorded for this gene in our reference set.
Inheritance pattern
Conditions caused by pathogenic TRIP12 variants typically follow autosomal dominant inheritance.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
UK clinical status
TRIP12 is included on several NHS Genomic Medicine Service PanelApp panels relevant to neurodevelopmental conditions. The gene holds green (high-evidence) classification on the Developmental Disorders Genotype-to-Phenotype (DDG2P) panel, the Fetal anomalies panel, and the Intellectual disability panel. This status reflects expert consensus that variants in TRIP12 are a recognised cause of these conditions and supports its inclusion in UK clinical genetic testing pathways for individuals with unexplained developmental delay or intellectual disability.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
How is TRIP12-related neurodevelopmental disorder inherited?
TRIP12-related conditions follow an autosomal dominant pattern, meaning a single pathogenic variant in one copy of the gene is typically sufficient to cause clinical features. Most cases arise from new (de novo) variants not inherited from either parent, though familial transmission can occur.
What does an E3 ubiquitin ligase do?
E3 ubiquitin ligases are enzymes that attach ubiquitin tags to specific target proteins, marking them for destruction by the cell's protein-recycling machinery. This process helps cells maintain proper protein balance by removing damaged, misfolded, or excess proteins.
Is TRIP12 tested in the NHS?
TRIP12 is included on NHS Genomic Medicine Service panels for intellectual disability and developmental conditions. Testing may be offered through the NHS when an individual's clinical features align with recognised testing criteria, typically following assessment by a clinical genetics service.